Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL654983 | 1.00 | CCR1 (0.42) | CCR1CHRM2CCR5ALDH1A1MAPT | |
| SCHEMBL654984 | 1.00 | CCR1 (0.42) | CCR1CHRM2CCR5ALDH1A1MAPT | |
| SCHEMBL995811 | 0.86 | HTR2B (0.46) | CCR1CHRM2CCR5ALDH1A1MAPT | |
| SCHEMBL995810 | 0.86 | HTR2B (0.46) | CCR1CHRM2CCR5ALDH1A1MAPT | |
| SCHEMBL7206976 | 0.86 | HTR2B (0.46) | CCR1CHRM2CCR5ALDH1A1MAPT | |
| SCHEMBL15478315 | 0.84 | CCR1 (0.46) | CCR1CHRM2CCR5TBXA2RTBXAS1 | |
| SCHEMBL654072 | 0.84 | CCR1 (0.50) | CCR1CHRM2CCR5TBXA2RTBXAS1 | |
| SCHEMBL436923 | 0.84 | CCR1 (0.59) | CCR1CHRM2CCR5TBXA2RHRH1 | |
| SCHEMBL436922 | 0.84 | CCR1 (0.59) | CCR1CHRM2CCR5TBXA2RHRH1 | |
| SCHEMBL654071 | 0.84 | CCR1 (0.50) | CCR1CHRM2CCR5TBXA2RTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6613905-B1 | Treating or preventing a disease associated with aberrant leukocyte recruitment and/or activation | MILLENNIUM PHARMACEUTICALS, INC. | 2003-09-02 | — | — | US | disclosed |